- Home
- PRCT vs CGEM Comparison
PRCT vs CGEM Comparison
Compare PRCT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRCT | CGEM |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRCT | CGEM |
|---|---|---|
| Price | $19.75 | $18.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $35.44 | $30.13 |
| AVG Volume (30 Days) | ★ 1.9M | 1.3M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,054,000.00 | N/A |
| Revenue This Year | $31.34 | N/A |
| Revenue Next Year | $24.52 | $5.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.22 | N/A |
| 52 Week Low | $19.35 | $5.68 |
| 52 Week High | $62.17 | $19.43 |
Technical Indicators
Market Signals| Indicator | PRCT | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 64.28 |
| Support Level | $19.64 | $11.87 |
| Resistance Level | $29.27 | $19.43 |
| Average True Range (ATR) | 1.46 | 1.12 |
| MACD | -0.16 | 0.11 |
| Stochastic Oscillator | 7.10 | 77.02 |
Price Performance
Historical ComparisonAbout PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.